Overall Financial Turnaround and Profit Improvement
FY2025 operating profit reached JPY 127.5 billion, up JPY 1.6 billion year‑on‑year (≈+1.3%). Profit before tax rose sharply to JPY 124.8 billion, an increase of JPY 174.8 billion YoY (driven largely by disappearance of prior large impairment losses and losses on share sales). Profit attributable to owners improved significantly and ROE improved to 4.7% (FY2026 target 5.2%). Net sales were broadly flat at JPY 2.0588 trillion (down JPY 8.8 billion, ≈-0.4%).
Strong Automotive Segment Performance
Automotive segment net sales increased to JPY 520.6 billion, up JPY 21.8 billion YoY (≈+4.4%), and operating profit rose to JPY 29.3 billion, up JPY 15.3 billion YoY (large improvement driven by better product mix, pricing policies and a weaker yen).
Solid Cash Generation and Healthy Balance Sheet
Operating cash flow was JPY 274.5 billion and free cash flow JPY 96.1 billion in FY2025. Total assets were JPY 2.9501 trillion (up JPY 60.4 billion) and D/E ratio stood at 0.37, indicating financial flexibility.
Major CapEx Completed; Lower CapEx Outlook
FY2025 CapEx was JPY 251.3 billion as major capacity expansions completed. FY2026 CapEx is forecast at JPY 190 billion (materially lower), with depreciation projected around JPY 183 billion — management intends to focus on collecting returns on recent investments.
Architectural Glass and Performance Chemicals Contributed Positively
Architectural Glass net sales grew to JPY 441.1 billion (up JPY 3.2 billion) and operating profit rose to JPY 17.3 billion (up JPY 0.9 billion) due to pricing policies and FX benefits in Europe/Americas. Performance Chemicals showed higher shipments and pricing benefits contributing to Chemical segment resilience.
Improved Strategic Business Outlook for FY2026
Company FY2026 guidance: net sales JPY 2.2 trillion (up JPY 141.2 billion YoY) and operating profit JPY 150 billion (up JPY 22.5 billion YoY). Strategic businesses are forecast to deliver net sales of JPY 560 billion and operating profit of JPY 80 billion, with Life Science improvements expected to be a major driver.